GP6: Platelet glycoprotein VI
Collagen receptor involved in collagen-induced platelet adhesion and activation.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on GP6, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Glenzocimab | Phase 2 | Acticor Biotech | Antibody | InhibitorPlatelet glycoprotein VI (GPVI) inhibitor | 0 |
- Platelet-type bleeding disorder 110.74
- Venous thromboembolism0.52
- Thromboembolism0.45
- Deep vein thrombosis0.45
- Platelet aggregation0.43
- Stroke disorder0.25
- Hereditary disease0.19
- Brain infarction0.19
- Abnormal bleeding0.15
- Thrombocytopenia0.12
- Atrial fibrillation0.09
- Acute myocardial infarction0.08
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3308912, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q9HCN6, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets